☰

Breast Cancer Clinical Trials

Last reviewed: November 15, 2026

Start with stage, ER/PR and HER2 reports, exact prior treatments and timing. An early-stage study before surgery, a study for residual disease after surgery, and a metastatic trial may use the same drug but have different entry requirements.

Answer a few questions to find clinical trials matched to your specific Breast Cancer situation.

A thorough search takes ~15 minutes — we'll email your results. No sign-up.

Find matching trials →

Stage and Treatment Goal Come First

Current Clinical Trial Landscape

Registry snapshot, November 15, 2026: the worldwide ClinicalTrials.gov search for Breast Cancer, interventional studies and Recruiting status returned 1,860 records. This broad result is not the number suitable for one person. Open the filtered registry search.

Research spans endocrine/pathway combinations, HER2-directed drugs, ADCs, immunotherapy, treatment sequencing, early-stage optimization and supportive care. These categories overlap; no fresh class-specific totals are claimed.

How Breast Subtypes and Biomarkers Fit Together

For focused HER2 information, see HER2-positive breast cancer trials and HER2-low breast cancer trials.

Approved Care and Research Cohorts Are Different

Selected U.S. examples show why stage, assay and prior treatment matter:

These selected examples are not a complete treatment guide. Discuss current local labels and alternatives with your oncology team; do not change treatment on this page alone.

Drug Names and Prior ADC Exposure

Sacituzumab tirumotecan, SKB264 and MK-2870 name the same study drug; sacituzumab govitecan is a different drug. T-DXd, SHR-A1811 and other HER2 ADCs are not interchangeable products. A drug's target does not establish that every subtype can enter its trial: patritumab deruxtecan NCT07060807 selects HR-positive/HER2-negative disease after specified endocrine/CDK4/6 treatment.

Have your stage, pathology and treatment history ready?

Find Matching Trials

Selected Trials by Subtype and Setting

All 57 cited records were checked November 15, 2026: 51 recruiting, five active but not recruiting and one unknown. Non-enrolling and unknown records are separated at the end. Every example carries its phase and recruitment label; a recruiting record does not guarantee an open local site/cohort or personal eligibility.

HR-positive/HER2-negative advanced disease: endocrine and pathway approaches

HR-positive/HER2-negative advanced disease: ADC studies

HR-positive/HER2-negative early-stage and locoregional recurrence studies

HER2-positive first-line advanced disease and maintenance

HER2-positive previously treated advanced disease

HER2-positive neoadjuvant and postoperative studies

TNBC first-line locally advanced or metastatic studies

TNBC previously treated advanced disease

TNBC or selected HR-low early-stage and residual-disease studies

HER2-low, ultralow and IHC 0 research

Supportive care: a different treatment goal

Active, not recruiting

Recruitment unknown: confirm current availability

Frequently Asked Questions

How do I find breast cancer trials for my subtype?

Bring stage, surgery and recurrence status, ER/PR percentages, HER2 IHC/ISH reports, exact biomarkers and prior treatment with dates and progression history. ClinTrialFinder suggests studies for discussion; the study team confirms protocol eligibility and site availability.

How many breast cancer trials are recruiting?

The November 15, 2026 worldwide ClinicalTrials.gov query for Breast Cancer, interventional studies and Recruiting status returned 1,860 records. This is a broad search, not a personalized count. Of the 57 selected records here, 51 were recruiting; five were active but not recruiting and one had unknown status.

Are HER2-positive, HER2-low, HER2-ultralow and IHC 0 interchangeable?

No. HER2-positive, low and ultralow labels depend on IHC/ISH findings and the relevant protocol or drug indication. Some IHC 0 trials include both absent and faint membrane staining. HR status and prior treatment still matter; bring the original report instead of relying on a shorthand subtype.

Can someone who already had surgery enter a neoadjuvant or adjuvant study?

It depends on the protocol. Neoadjuvant studies generally start before surgery, while adjuvant studies may require specific pathological risk, residual disease or a minimum/maximum duration of prior endocrine therapy. A high stage alone does not establish eligibility for a metastatic trial.

Does a breast ADC trial accept every subtype or someone who already had an ADC?

No. NCT07060807 selects HR-positive/HER2-negative advanced disease after specified endocrine/CDK4/6 treatment, and NCT05950945 excludes prior ADC exposure. Zanidatamab NCT06435429 instead requires prior T-DXd progression or intolerance and multiple HER2-directed lines. Read the actual treatment and subtype criteria.

Is camizestrant research the same as the ESR1-triggered approved switch?

No. The approved camizestrant/CDK4/6 switch follows detection of an ESR1 mutation during aromatase-inhibitor/CDK4/6 therapy and was studied without progression. Early-stage CAMBRIA and upfront advanced-disease studies are different cohorts. An ESR1 result alone does not establish eligibility for every camizestrant study.

Find Breast Cancer Trials Matched to Your Situation

Enter your subtype, biomarkers (HER2, ER/PR, BRCA, PIK3CA), and treatment history to get AI-matched results in minutes.

Find Matching Trials